Process Impurities: Don't Let PEI Or HCP Derail Your Biotherapy
Source: MilliporeSigma
Many impurities are present in or generated during biotherapy manufacturing. We will review strategies within product characterization to de-risk the manufacturing process for monoclonal antibodies (mAb) and cell and gene therapies. We will discuss how to effectively detect and characterize host cell proteins (a factor in mAb therapies and cell and gene therapies), and polyethylenimine (PEI), used in cell and gene therapy products.
VIEW THE WEBINAR!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Biosimilar Development? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
MilliporeSigma
This website uses cookies to ensure you get the best experience on our website. Learn more